These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31673941)

  • 1. ASO Author Reflections: Evaluation of Tumor Regression After Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma-How to Do It?
    Takeda FR; Tustumi F; Cecconello I
    Ann Surg Oncol; 2020 Apr; 27(4):1248-1249. PubMed ID: 31673941
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis.
    Thomas M; Borggreve AS; van Rossum PSN; Perneel C; Moons J; Van Daele E; van Hillegersberg R; Deng W; Pattyn P; Mook S; Boterberg T; Ruurda JP; Nafteux P; Lin SH; Haustermans K
    Acta Oncol; 2019 Oct; 58(10):1358-1365. PubMed ID: 31432736
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: The Challenging Journey from cCR to pCR After Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma.
    Chen KN
    Ann Surg Oncol; 2024 Jul; 31(7):4317-4320. PubMed ID: 38366184
    [No Abstract]   [Full Text] [Related]  

  • 4. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West.
    Moaven O; Wang TN
    Surg Clin North Am; 2019 Jun; 99(3):479-499. PubMed ID: 31047037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?
    Ilson D; Lordick F
    Lancet Oncol; 2018 Oct; 19(10):1285-1286. PubMed ID: 30528077
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Huang X; Tan L
    Ann Surg Oncol; 2024 Feb; 31(2):899-900. PubMed ID: 38006528
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
    Chen CY; Li CC; Chien CR
    World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASO Author Reflections: A Novel, Sensitive, and Effective Index in Predicting Therapeutic Response of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Ann Surg Oncol; 2024 Jan; 31(1):241-242. PubMed ID: 37838649
    [No Abstract]   [Full Text] [Related]  

  • 11. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
    Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
    [No Abstract]   [Full Text] [Related]  

  • 12. Choosing the best treatment for esophageal cancer : criteria for selecting the best multimodal therapy.
    Hölscher AH; Bollschweiler E
    Recent Results Cancer Res; 2012; 196():169-77. PubMed ID: 23129373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASO Author Reflections: Timing of Oesophagectomy After Neoadjuvant Chemoradiotherapy for Locally Advanced Oesophageal Cancer.
    Xiao X; Cheng C; Cheng L; Yuan Y
    Ann Surg Oncol; 2023 Feb; 30(2):897-898. PubMed ID: 36322273
    [No Abstract]   [Full Text] [Related]  

  • 14. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma.
    Kauppila JH; Wahlin K; Lagergren P; Lagergren J
    Int J Cancer; 2019 Mar; 144(6):1284-1291. PubMed ID: 30168595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
    Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
    Li F; Ding N; Zhao Y; Yuan L; Mao Y
    Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
    Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
    BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASO Author Reflections: Biomarkers for Neoadjuvant Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma.
    Okumura H; Noda M; Natsugoe S
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):715-716. PubMed ID: 30288651
    [No Abstract]   [Full Text] [Related]  

  • 20. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
    Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
    Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.